To hear about similar clinical trials, please enter your email below
Trial Title:
Molecular Analysis and Treatment Options of Thymic Malignancies
NCT ID:
NCT05667948
Condition:
Thymic Epithelial Tumor
Thymic Carcinoma
Thymic Cancer
Conditions: Official terms:
Thymoma
Neoplasms, Glandular and Epithelial
Thymus Neoplasms
Immunomodulating Agents
Conditions: Keywords:
thymic malignancy
thymoma
chemotherapy
targeted therapy
immunotherapy
molecular landscape
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Drug
Intervention name:
Chemotherapy
Description:
different treatments based on the molecular analysis
Other name:
targeted therapy
Other name:
immunotherapy
Summary:
Thymic malignancies are the most common tumors of the anterior mediastinum, though
surgery and radiation often effectively treat thymic carcinomas, a minority continue to
progress and eventually lead to death. Therefore, there is an unmet need for more
effective therapies for thymic malignancies. Considering the role of molecular
alterations has yet to be defined in the treatment of thymoma and thymic malignancies,
there is an urgent recognition that molecular alterations in the thymic malignancies are
important to predict response and survival for novel targeted therapies.
In summary, identification of genetic alterations in thymic malignancies is increasingly
essential to perform molecular diagnostics and individualized treatments. This project
aims to create a registry of patients with thymic malignancies to further the
characterization of molecular alterations and develop (novel) treatments based on the
detection.
Criteria for eligibility:
Study pop:
Participants with thymic malignancies are with the standard treatment and/or are enrolled
in the clinical trials.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Histologically proven diagnosis of thymic malignancies
- 18 years of age or older
- Ability to understand and the willingness to sign a written informed consent
document
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Xiaomin Niu
Address:
City:
Shanghai
Zip:
200030
Country:
China
Status:
Recruiting
Contact:
Last name:
Xiaomin Niu
Phone:
021-22200000
Email:
ar_tey@hotmail.com
Start date:
January 1, 2016
Completion date:
December 31, 2026
Lead sponsor:
Agency:
Shanghai Chest Hospital
Agency class:
Other
Source:
Shanghai Chest Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05667948
